Verrica Pharmaceuticals Inc. VRCA
3.14 USD -0.06 (-2.03%)
Regular-session close
3.10 -0.04 -1.27%
After hours · Nov 17, 4:32 PM ET
2.77 Day range 3.66
2.77 52-week range 9.82
- YTD
- -62.21%
- 1 year
- -15.82%
News
seekingalpha.com Verrica Pharmaceuticals Inc. (VRCA) Q3 2026 Earnings Call Transcript Verrica Pharmaceuticals Inc. (VRCA) Q3 2026 Earnings Call Transcript
marketbeat.com Verrica Pharmaceuticals Q3 Earnings Call Highlights Verrica Pharmaceuticals NASDAQ: VRCA reported record quarterly U.S. revenue for its molluscum treatment YCANTH in the third quarter of 2026, even as total revenue fell from a year earlier and its net…
globenewswire.com Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results – Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million –
globenewswire.com Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London WEST CHESTER, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of…
globenewswire.com Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026 WEST CHESTER, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for…
globenewswire.com Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility – Company's achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million – – Capital now available to support continued growth of the YCANTH®…
defenseworld.net Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock Has Average Price Target of $12.67 According to Brokerages Verrica Pharmaceuticals Inc. (NASDAQ: VRCA - Get Free Report) has been given an average recommendation of "Hold" by the five ratings firms that are currently covering the firm, Marketbeat.com…
globenewswire.com Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences – Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration –
globenewswire.com Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences – Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –
globenewswire.com Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of…
globenewswire.com Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027 – Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment – – Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current…
marketbeat.com Verrica Pharmaceuticals Q2 Earnings Call Highlights Verrica Pharmaceuticals NASDAQ: VRCA reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common…
seekingalpha.com Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
globenewswire.com Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for…
globenewswire.com Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of…
globenewswire.com Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan - - Verrica maintains ownership of global…
globenewswire.com Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of…
globenewswire.com Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of…
marketbeat.com Verrica Pharmaceuticals Q1 Earnings Call Highlights Verrica Pharmaceuticals NASDAQ: VRCA reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development…
